Northera
ApprovedSmall molecule
Northera is one of 50 small molecule programs targeting Fatigue. It is currently in Approved.
3
Indications
3
Total Trials
0
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
190 competitors in Spinal Cord Injury
#DrugCompanyPhaseTrials
1Medrol
PfizerPhase 3
Proamatine
TakedaPhase 3
Minocin
TTriax
Phase 3
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Cesamet
BBausch Health Americas, Inc.
Phase 3
Genotropin
EMD SeronoPhase 3
Robitussin
PfizerPhase 2
Myrbetriq
AstellasPhase 2
Northera
NNew York Medical College
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Fatigue1 trial
Spinal Cord Injury1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Northera. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- NNew York Medical College